Relevant concomitant care permitted or prohibited during the
trial
Treatment with any or all of the following therapies is permitted during
the participating studies and not a reason to withhold study medication:
deep vein thrombosis prophylaxis with UFH or low molecular weight
heparin (LMWH); ‘full’ therapeutic dose UFH or LMWH for a recognised
clinical indication; non-heparin anticoagulants; anti-thrombotic
medications; protamine; prone positioning; and inhaled nitric oxide.
There are no prohibitions during the trial.